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Adenoviral urokinase-type plasminogen
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and Alberto Smith, PhD, London, United Kingdom
Introduction: There is an increase in the natural level of urokinase-type plasminogen activator (uPA) activity within the
thrombus during venous thrombus resolution. The use of uPA as a thrombolytic agent in the treatment of acute
iliofemoral deep vein thrombosis is not suitable for all patients. This study aimed to determine whether thrombus
resolution could be enhanced by upregulating uPA expression using adenoviral gene transfer as an alternative method of
delivery.
Methods: The production of functional uPA by an adenoviral gene construct (ad.uPA) was confirmed by a colorimetric
substrate assay and fibrin plate lysis. Thrombus was formed in the inferior vena cava of wild-type mice and injected,
48-hours after induction, with either a control virus at 108 plaque-forming units (pfu) or ad.uPA at 107 or 108 pfu.
Thrombi were removed and weighed 7 days after treatment. Activity of metalloproteinase (MMP) 2 and 9 was measured
by zymography and the release of vascular endothelial growth factor (VEGF) and D-dimer levels by enzyme-linked
immunoabsorbent assay. The results were expressed as a mean  SEM. Values were standardized for wet weight or for
soluble protein content (mg/sol protein).
Results: Treatment with ad.uPA reduced thrombus weight by twofold compared with thrombi treated by control virus
(15.1  1.1 mg vs 7.4  1.3 mg, P  .004). Urokinase activity (17  3 pg/mg wet weight) was detected in all treated
thrombi, but there was no dose-dependent effect. D-dimer activity was increased twofold after treatment with ad.uPA
(1.7  0.15 ng/mg of sol protein vs 0.8  0.1 ng/mg of sol protein, P  .0015) and was associated with a reduction in
thrombus size (P  .03). Urokinase overexpression did not affect the activity of MMP2, MMP9, or VEGF in the
thrombus.
Conclusion: Increasing urokinase activity within the thrombus significantly enhanced natural thrombus resolution by a
fibrinolytic action. Therapeutic delivery of ad.uPA in patients may provide a novel method of treating deep vein
thrombosis. ( J Vasc Surg 2006;44:1085-90.)
Clinical Relevance: The use of urokinase as a thrombolytic agent in the treatment of acute iliofemoral deep vein
thrombosis is not suitable for all patients. This study aimed to determine whether thrombus resolution could be enhanced
by upregulating urokinase expression using adenoviral gene transfer as an alternative method of therapeutic delivery. The
study shows that by increasing urokinase activity within the thrombus, natural thrombus resolution can be significantly
enhanced. The delivery of ad.uPA in patients may provide a novel method of treating deep vein thrombosis.Deep vein thrombosis is almost exclusively treated by
anticoagulation, which reduces thrombus propagation
and, hence, pulmonary embolism, but does not enhance
thrombus resolution. Anticoagulant treatment alone
does not reduce the risk of developing a post-thrombotic
limb. Prospective randomized studies are currently being
conducted to discover whether catheter-directed throm-
bolysis reduces the development of post-thrombotic
limbs compared with treatment by anticoagulants alone.
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quired for thrombolysis restrict its use in the postopera-
tive period, and this type of treatment is of limited value
when the thrombus has been present for  10 days.1
Alternative methods of delivering fibrinolytic agents are
therefore worth exploring.
Studies in a rat model of venous thrombosis have
shown that during natural resolution of venous thrombi,
there is an increase in the activity of the fibrinolytic
mediators tissue-type plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA).2 The levels
of uPA were always found to be greater than those of
tPA. Subsequent gene knockout studies have shown that
deletion of the gene encoding for uPA markedly inhib-
ited normal thrombus resolution, but the tPA gene
knockout had no effect.3 These results led us to speculate
that increasing the expression of uPA in the thrombus
might enhance its resolution.
We have previously shown that thrombus recanaliza-
tion can be enhanced by upregulating vascular endothe-
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bus.4 Adenovirus expression cassettes provide a means of
generating sustained amounts of the transfected gene
product. These vectors are now a common and effective
method of gene delivery.5,6 The aim of this study was to
determine whether increasing the fibrinolytic environ-
ment inside the thrombus using adenoviral-assisted
transfer of the uPA gene might enhance thrombus reso-
lution. A secondary aim was to discover the possible
mechanism of accelerated resolution.
METHODS
Thrombus formation. A combination of low flow
and endothelial damage was used to induce the forma-
tion of venous thrombi in the vena cava of BALBc mice.3
Under Home Office approval, the mice were anesthe-
tized using isoflurane (Baxter Health Care Ltd, Berk-
shire, UK), and a midline laparotomy was performed.
The inferior vena cava was mobilized, and a 2-0 silk tie
was placed around the vessel just inferior to the left renal
vein. A 3-0 Prolene suture (Ethicon, Somerville, NJ) was
placed longitudinally over the inferior vena cava and the
silk suture tied over the top. The Prolene suture was then
removed to produce a severe stenosis that restricted the
blood flow by approximately 90%.3,7,8 Endothelial dam-
age was created by application of a microvascular clamp
to the vessel at two separate positions below the renal
vein for 20 seconds at a time. This produced a thrombo-
sis in approximately 98% of treated mice.
Culture of adenovirus. Murine adenovirus serotype
(Ad5), ElaE3 deleted, containing the gene cassette for
urokinase (ad.uPA) was obtained from Prof Tom Sis-
sons, Department of Internal Medicine, University of
Michigan Medical Center (Ann Arbor, Mich).9 The virus
was grown in human embryonic kidney cells (HEK-293)
and maintained in 10% Dulbecco’s Modified Eagle’s
Media. Before purification, functional uPA production
by this construct was confirmed by both plasminogen
substrate conversion and fibrin plate analysis in condi-
tioned media from the HEK-293 cells used to grow the
ad.uPA.
Urokinase (uPA) substrate activity assay. Urokinase
(uPA) activity was measured in duplicate samples of the
conditioned media by using a specific synthetic peptide
substrate (S2444).10 Substrate conversion was measured
as a change in absorbance at 405 nm. Sample value was
interpolated from a standard curve produced from a
World Health Organization uPA standard (NIBSC,
Hertfordshire, UK).
Urokinase (uPA) fibrinogen plate analysis. A gel
was formed using fibrinogen (0.4%, Sigma, Dorset, UK),
agarose (0.0015% Sigma), lys-plasminogen (25 g/mL)
and thrombin (5 IU/mL) in Dulbecco’s phosphate buff-
ered saline (DPBS), pH 7.4, (Sigma). Serially diluted
HEK-293–conditioned media and active uPA standards
(NIBSC) were added to wells made in the fibrin gel and
incubated for 12 hours at 37°C. The areas of lysis (mm2)
were measured for a set of four standards and the sample.The sample measurement was interpolated from the
standard curve.
Viral purification and titre. AdenoX Maxi prep kits
(BD Biosciences, Oxford, UK) were used to purify the
adenovirus, and the titre of infectious particles was esti-
mated using the AdenoX titre kit according to the man-
ufacturer’s instructions. The same batch of adenovirus
was used for all the experiments in this study.
Ad.uPA injections. Venous thrombus was formed
in the inferior vena cava of 28 wild-type mice (BALBc).
Mice were treated with different doses of ad.uPA con-
struct (107 or 108 plaque-forming units, pfu) by direct
injection of 10 L of the construct into the thrombus
using a 34-gauge Hamilton syringe (Hamilton,
Bonaduz, Switzerland) 48 hours after induction. The
same volume of the ad.LacZ construct (108 pfu) was
injected into a cohort of eight mice to act as control.
Thrombi were harvested 7 days after injection by
resecting the vena cava and separating the contained
thrombus, which was immediately snap frozen in liquid
nitrogen and weighed. A further cohort of 20 BALBc
mice were treated with either murine ad.uPA 108 pfu or
108 pfu of the control adenovirus carrying the reporter
gene (ad.LacZ).
Thrombus analysis. The thrombus was homoge-
nized in phosphate-buffered saline (pH 7.4). Thrombus
uPA activity was measured using a murine-specific, func-
tional uPA bioimmunoassay kit (Molecular Innovations,
Southfield, Mich). Activity was standardized against the
wet weight of thrombus. Aliquots of the homogenates
were snap frozen in liquid nitrogen. VEGF antigen was
measured using a quantitative sandwich enzyme immu-
noassay (R&D Systems, Oxford, UK), D-dimer levels
were measured by enzyme-linked immunoabsorbent as-
say (Asserachom, D-Di, Axis-Shield, Kimbolton, UK),
and matrix metalloproteinase (MMP) activity was quan-
tified by zymography11 (Invitrogen, Paisley, UK). Val-
ues were standardized against the soluble protein (sol
protein) content of the extract.
Statistical analysis. All analysis were performed with
Prism (GraphPad Software Inc, San Diego, Calif). The
unpaired Student’s t test was used for comparisons be-
tween the two treatment groups because the data were
normally distributed. Values were expressed as means 
standard error.
RESULTS
Functional uPA production by the ad. uPA vector.
Analysis of conditioned media obtained from the culture
of ad-uPA–infected HEK-293 cells demonstrated func-
tional uPA activity. Plasminogen substrate conversion
assays and fibrin plate analysis (Fig 1) gave values of
100 IU/mL and 400 IU/mL, respectively. No func-
tional uPA activity was detected by either, but there was
no increase in uPA activity with the higher adenoviral
dose (ad.uPA at 107pfu, 16.5  0.3 pg/mg wet weight;
ad.uPA at 108 pfu, 14.5  0.4 pg/mg wet weight). No
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ad.LacZ.
Thrombus size. Thrombus weight was reduced by
approximately half in all treated groups compared with
the controls (ad.uPA 7.34  1.1 mg vs control 15.1 
1.1 mg, P  .0004, Fig 2). There was, however, no
enhanced effect on thrombus size with increasing doses
of the adenovirus (Fig 2).
VEGF, MMP, and D-dimer levels. Thrombus size
was again reduced by treatment with ad.uPA compared
with controls (ad.uPA 4.04  0.9 mg vs control 6.8 
1.9 mg, P  .028). Measurable levels of VEGF protein
were present in all the thrombi, but there was no differ-
ence in the VEGF levels between the ad.uPA or control
virus-treated groups, (23.44  3.7 pg/mg sol protein vs
Fig 1. Measurement of urokinase-type plasminogen activator
(uPA) activity by fibrin plate lysis. Conditioned media taken from
HEK-293 kidney cells treated with (A) nothing, (B) ad.blank, (C)
ad.LacZ, and (D) ad.uPA.
Fig 2. Thrombus weight at 7 days after treatment with either
ad.uPA or a control (ad.LacZ).22.34  2.5 pg/mg sol protein, P  .82). VEGF wasalso present in the vein walls, but again the levels were
not increased by the ad.uPA treatment (21.58  6.0
pg/mg sol protein vs 19.70  2.8 pg/mg sol protein, P
 .79).
MMPs 2 and 9 were detectable in all the thrombi and
vein walls, but no difference in activity was detectable
between the ad.uPA treated and control virus-treated
groups (P  .05 for all comparisons; Table).
Approximately twice the concentration of D-dimer
levels was found in thrombus extracts obtained from the
ad.uPA-treated group compared with controls (1.71 
0.15 ng/mg sol protein vs 0.84  0.1 ng/mg sol
protein, respectively, P  .0015; Fig 3). Increased D-
dimer levels were associated with a reduction in throm-
bus size (P  .003; Fig 4).
DISCUSSION
We have previously shown that monocyte ingress in
Fig 3. Comparison of D-dimer levels between thrombi treated
with ad.uPA and control, ad.LacZ-treated thrombi.
Fig 4. Correlation between D-dimer levels in the thrombus and
thrombus weight.natural thrombus resolution is dependent on the expres-
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promotes thrombus resolution by assisting monocyte
recruitment into the thrombus, which facilitates revascu-
larization and remodelling.12 The uPA released by the
cells that enter the thrombus could also promote resolu-
tion through a direct fibrinolytic action.
Adenoviral-mediated transfection of uPA has been
successfully used to upregulate fibrinolysis in animal
models of pulmonary fibrosis.11 To our knowledge, this
is the first report of its use to increase uPA activity in the
thrombus to improve resolution. The present study
shows that injection of an ad.uPA gene construct directly
into the venous thrombus resulted in increased uPA
activity in the thrombus and more than halved the
thrombus size compared with controls. The effect of
treatment on restoration of blood flow in the vein (re-
canalization) was, however, not measured in this study
because the thrombi were weighed and homogenized for
biochemical analysis. Treatment with ad.uPA was associ-
ated with a significant increase in the D-dimer concen-
trations in the thrombus, which were inversely correlated
with the size of the thrombus. These data strongly
suggest that the raised levels of uPA enhanced thrombus
resolution through a fibrinolytic action.
It was thought that the higher uPA concentrations
produced after treatment with ad.uPA might have en-
hanced thrombus resolution by activating latent protein-
ases.13,14 These enzymes are known to increase extracel-
lular matrix degradation and have been previously found
in resolving venous thrombi (MMP2 and MMP9).15 In
this study, both latent and active MMP-2 and MMP-9
were present in the thrombus, but there was no differ-
ence in the levels of active MMPs in the vein wall or the
thrombus in animals treated with ad.uPA compared with
controls.
Urokinase is also involved in the proteolytic activa-
tion and release of growth factors from the extracellular
matrix.16 Increasing the uPA activity within the throm-
bus might, therefore, lead to higher local levels of VEGF.
This cytokine is a potent angiogenic agent17 that pro-
motes tissue remodeling18 and is normally expressed
during thrombus resolution.16 Direct injection of VEGF
and a plasmid carrying the VEGF gene, have been shown to
enhance thrombus recanalization and promote monocyte
recruitment into the thrombus.4,19 VEGF was present in
the thrombi of all animals in this study, but treatment with
ad.uPA did not produce higher levels of available VEGF in
either the vein wall or thrombus.
The ad.uPA construct produced picogram quantities
of active uPA in the thrombus, which is substantially
smaller than the pharmacologic doses normally used in
thrombolysis.1 This would potentially reduce the risk of
bleeding complications associated with local or systemic
treatment. There is normally a lag time of up to 24 hours
before adenoviral constructs begin to generate active
protein, with maximal production between 3 and 5
days.20 Analysis of uPA activity in the thrombus at 7 days
may, therefore, not have reflected the maximum fibrino-lytic activity produced by the viral construct. Production
of protein by adenoviral constructs can last for up to 14
days,21,22 which may lead to further enhancement of
thrombus resolution.
It is also conceivable that uPA might have a greater
effect on thrombus resolution if the construct were
administered earlier. The time course of protein produc-
tion by adenoviral vectors is influenced by the type of
promoter and the generation of the vector used.23,24
Inserting the uPA gene into a third-generation adenovi-
ral vector with a different promoter should increase the
rate and duration of uPA expression, which may have a
greater effect on thrombus resolution. The use of third-
generation viral vectors that are devoid of genes produc-
ing viral proteins may also overcome the problems of
immunogenicity.
Increasing the dose of ad.uPA had no effect on
thrombus size. This could reflect (1) a limit to the degree
of transfection as a result of the relatively small numbers
of nucleated cells present in the early thrombus (only
nucleated cells are capable of expressing the protein), (2)
the inability of the injected material to diffuse through-
out the thrombus, or (3) loss of injected material into the
circulation or surrounding tissues. These factors will be
addressed in subsequent studies.
The effect of a single ad.uPA dose might not be as
effective in the much larger volume of thrombus found
in human veins, although a method of delivering a more
uniform distribution of greater quantities of the ad.uPA
construct may overcome this problem. Treatment with
adenoviral constructs is currently expensive, however.
Improvements in the technologies used for their produc-
tion and isolation would be needed before adenoviral-
based therapies could be used for the treatment of deep
vein thrombosis in the clinic.
A number of further studies are now required to deter-
mine the optimal conditions for improved ad.uPA delivery.
1. Treating the thrombus with ad.uPA at different times
before and after thrombus formation would help to
establish a suitable dosing regimen.
2. Targeting the ad.uPA by specifically transfecting mono-
cytes that are recruited into resolving thrombus might
also result in greater quantities of uPA expression. Our
recent work has shown that targeting transfection to
monocytes may be possible by coating the viral particles
in sugars that bind to specific receptors on these cells.25
This would prevent loss of the adenovirus to the liver
after systemic administration.
3. Joint administration of adenoviruses carrying the genes
for uPA and its substrate, plasminogen, or a bicistronic
construct carrying the genes for both uPA and its sub-
strate, also merits investigation. This method has the
potential to provide a greater fibrinolytic drive within
the thrombus.
4. It may be possible to combine catheter-directed throm-
bolytic therapy with local adenoviral delivery to give a
prolonged and sustained increase in the level of fibrino-
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enoviral impregnation of stents prior to their insertion
has already been used to prevent neointima formation
and graft thrombosis in arterial disease and may also be
of use in venous disease.26-29
5. The use of alternative viral vectors or the use of future
generations of less immunogenic viral vectors with more
powerful promoters may improve transfection and pro-
vide higher andmore sustained levels of protein produc-
tion within the thrombus.
These studies are now underway in our unit and await
completion. It is hoped that this approach might offer a
novel method of enhancing thrombus resolution, which
may avoid the risks of hemorrhage. Table.
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